Xingsheng Hu

Allele Frequency–Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors

Zhijie Wang, Jianchun Duan, Guoqiang Wang et al. · Journal of Thoracic Oncology · 2019 · 92 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients

Xingsheng Hu, Dongyong Yang, Yalun Li et al. · Cancer Biology and Medicine · 2019 · 55 citations · Full text

Life Sciences, Genetics, Oncology +17

Circular RNA profiling identified as a biomarker for predicting the efficacy of Gefitinib therapy for non-small cell lung cancer

Yutao Liu, Xiaohong Han, Puyuan Xing et al. · Journal of Thoracic Disease · 2019 · 40 citations · Full text

Medicine, Molecular Biology, Oncology +17

Silence of lncRNA MIAT-mediated inhibition of DLG3 promoter methylation suppresses breast cancer progression via the Hippo signaling pathway

Xingsheng Hu, Sijia Yu, Shishan Deng et al. · Cellular Signalling · 2020 · 38 citations

Medicine, Molecular Biology, Molecular Genetics +16

A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer

Xingsheng Hu, Lin Wang, Lin Lin et al. · Chinese Journal of Cancer Research · 2016 · 29 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +17